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ABSTRACT 
BACKGROUND:  Multi drug resistant Tuberculosis (MDR-TB) is a serious public 
health concern in many parts of the world. As per the WHO- 2010 global report on   
Surveillance and response 3.6% of all incident TB cases globally are multidrug resistant. 
In this regard, there is an increasing demand for timely, reliable and comprehensive drug 
susceptibility testing (DST) as MDR-TB surveillance is being geared up. The intent of 
this analysis is to determine whether there is a need to continue routine confirmatory DST 
testing at CDC in addition to just sending the isolates for genotyping. Analysis is done by 
measuring the discordance between the results of laboratory DST at CDC and the local 
labs drug type, drug testing concentrations, and study sites. 
 
METHODS: The data for this analysis was provided by the Tuberculosis Trials 
Consortium (TBTC), CDC. Data for this analysis was collected over nearly two decades 
(1993-2011), gathered from 7 clinical trials. Discordance between the local and CDC lab 
DST results was measured using Kappa statistic. Sensitivity and specificity analysis was 
done by taking the CDC DST lab results as the gold standard. Discordance levels were 
calculated by local sites and baseline drug resistance for each antibiotic in each study was 
measured. 
 
RESULTS: Average Kappa values for inter rater agreement for all the studies was 0.6444 
whereas the overall level of discordance across all studies is 7.786%.   Drug resistance at 
baseline was highest for Isoniazid and Streptomycin (except Study 23 and 22). 
 
CONCLUSION: Though the current results show few DST result discordances between 
local and CDC labs, it is better to continue to send isolates to the centralized lab (CDC) in 
view of the worldwide threat of drug resistant TB epidemic, the recommendations of the 
current literature and the benefits of reliable confirmatory testing services and availability 
of other molecular diagnostic methods.   
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CHAPTER I 
INTRODUCTION 
                           Tuberculosis (TB), one of the most deadly diseases throughout history, 
is the second leading cause of death among infectious diseases. While effective treatment 
regimens are continuously being improvised, emergence of multidrug resistance to anti 
TB drugs is currently a huge hindrance in combating this lethal infection. TB Drug 
susceptibility testing (DST), documented to be one of the most complex procedures to 
standardize in the Mycobacteriology laboratory requires technical expertise to produce 
valid and reliable results and requires up to 8 weeks to get results by commonly used 
methodology 51.  DST on initial isolates from all patients enrolled in Tuberculosis Trials 
Consortium (TBTC) studies is done to identify an effective anti-TB regimen at Local 
Public Health Laboratories to assure an effective treatment regimen is prescribed. 
Subcultures of initial isolates from local labs are subsequently sent to the 
Mycobacteriology laboratory (CDC) for confirmatory DST.  
                           The goal of this study is to measure the discordance between the results 
of laboratory DST at CDC and the local labs. The intent of the analysis is to determine 
whether there is a need to continue routine confirmatory DST testing at CDC in addition 
to just sending the isolates for genotyping. Also measuring discordance by various factors 
such as the drug type, drug testing concentrations, and study sites is critical part of this 
analysis. Since the clinical decisions are based on the local lab results, the reliability of 
lab test results and the study site’s potential for DST lab testing is imperative. Another 
aspect of this analysis is to measure how much drug resistance exists among patients 
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entering TBTC studies (22, 23, 24, 25, 27, 28 and 29) as most studies assume a pan 
sensitive population. This will help understand if the current lab techniques are enabling 
the timely detection of drug resistance in new patients. At sites with considerable 
background rates of drug resistant TB, suggestions to use new molecular DST (Rapid 
MDR TB identification tests such as Gene xpert) which give results in hours might be 
evaluated. 
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CHAPTER II 
REVIEW OF LITERATURE 
2.1 Global burden of Tuberculosis 
                 Tuberculosis (TB), a worldwide pandemic, is the seventh leading cause of 
mortality globally and ranks second only to human immunodeficiency virus (HIV) as a 
cause of death from an infectious agent 1.  TB bacilli infect around one third of the 
world’s population, approximately 2 billion people 3. According to the 2009 WHO report, 
the estimated global incidence of TB was 9.4 million, the estimated global prevalence 11 
million with the largest proportion of estimated cases occurring in South-East Asia region 
(34%), the Western Pacific region (21%) and African Region (30%) 2. Among the 22 
High Burden Countries (HBCs) which account for 80% of new cases every year, India, 
China, Indonesia, South Africa and Nigeria are among the highest TB incidence countries 
4
. 
2.2 TB history and overview: 
               TB is an airborne, infectious disease caused by Mycobacterium tuberculosis 
(MTB) that primarily attacks the lungs and sometimes other organs such as kidney, spine 
and brain. It can cause two reactions in the human body: either the latent TB infection 
(LTBI) or active TB disease. Latent infection occurs when the person is infected with 
MTB (shows no symptoms) but the immune system fights progression to TB disease. 
People with latent TB cannot spread the bacteria and can be identified by tuberculin skin 
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Test (TST) or special TB blood test. Active TB disease occurs when the bacteria are 
rapidly multiplying in the body and the immune system is incapable of stopping the 
proliferation. Most often (around 75%) active TB is pulmonary (affecting the lungs). 
Extra–pulmonary TB is less frequent at higher rates in immune compromised individuals. 
(In this paper we follow common usage and take TB to mean pulmonary tuberculosis.  
Others forms will be specified.). Clinical manifestations of pulmonary TB include 
chronic cough, weight loss, fever, fatigue, sweating, and blood tinged sputum 18, 19, 20. 
              Evidence exists in the form of skeletal remains with TB (4000 BC) and 
tubercular decay in the spines of Egyptian mummies (3000-2400 BC), thus proving that 
TB is one of the oldest infectious diseases 21. With the industrial revolution in 1600 AD, 
TB became widespread with the growth and expansion of urban areas. The same 
epidemiological trend is reflected in current urban areas wherein overcrowding, lack of 
sanitation and malnutrition are the breeding grounds for TB 22. 
2.3 Close association of TB with poverty: 
             Along with malaria and HIV, TB is a preventable and curable disease most 
closely linked to poverty. Ninety-eight percent of TB deaths and 95% of TB incidence 
occur in low and middle income countries 5.  According to WHO estimates, average 
incidence in low income countries is twenty times higher than in high income countries. 
Several studies done in different locations showed that over -crowding, poor living and 
working settings, HIV, malnutrition, homelessness, smoking, alcohol abuse, indoor air 
pollution are environmental risk factors for TB 6,7,8,10 . TB not only thrives on poverty but 
also worsens it. Estimates show that TB might lead to loss of 20-30% of annual wages 
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among the poor 13. Even in the developed world, similar epidemiology is documented - 
higher rates of TB are found in poorer, underprivileged sections of the society and thus 
underlining the close interaction between social determinants of health and existence of 
TB 8,9,10,11,12,13,17. As the world’s population is rising, the number of people living in 
poverty is also rising- posing a real threat to TB eradication programs. 
             The importance of tuberculosis among other infectious diseases is chiefly 
attributed to the high case fatality rate among untreated and improperly treated patients. 
According to Styblo & Enarson, two thirds of untreated smear positive patients will die 
within five to eight years and most of them in the first 18 months 24. Even in smear 
positive patients receiving anti TB drug treatment, the case fatality rate can be more than 
10 percent in areas with low adherence rates or high HIV co infection and drug resistance 
rates 25. 
2.4 Current trends in TB: 
              Currently the incidence of TB is gradually declining in most countries (since the 
peak in 2004) and also the death rate is declining (since 2000) due to the diagnosis and 
treatment of TB. However, treatment programs have not had a major, detectable impact 
on incidence on the whole 65. In the United States, there has been a steady decline and in 
2010 there was lowest recorded incidence 66, 67. 
2.5 Evolution of public health approaches for tackling TB: 
              The approaches to control TB changed over the years (1948-present). The DOTS 
strategy formulated by the WHO in 1993 emphasized the five elements needed for 
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controlling this world wide public health emergency which included political 
commitment, increasing case detection rate using sputum smear microscope, 
standardizing short course therapies including (Directly Observed Therapy) DOT, regular 
supply of drugs and this DOTS strategy is estimated to be one of the most cost effective 
interventions currently available 33, 34.   
2.6 TB drugs: 
              Before the introduction of the anti TB drugs in the 1950s and the development of 
drug regimens during 1980s, mortality due to pulmonary TB was estimated to be 50%. 
The discovery of streptomycin and its clinical use as the first specific anti tuberculosis 
drug is a significant milestone in efforts to fight TB 23. Anti TB drugs today are classified 
into first line, second line and third line drugs. First line drugs are highly effective and 
essential components of a short course regimen while second line drugs frequently 
produce adverse events. Ethambutol (E or EMB), Isoniazid (H or INH), Pyrazinamide (Z 
or PZA), Rifampicin (R or RMP) (equivalent to Rifampin (RIF) in US), streptomycin (S 
or STM) are classified as first line drugs. Second line drugs include aminoglycosides, 
polypeptides, fluoroquinolones, thioamides, cycloserine, p-aminosalicyclic acid 26. 
Examples of newly discovered drugs are Fluoroquinolones- levofloxacin, gatofloxacin 
and moxifloxacin 35. The current recommended drug regimen for most patients with 
pulmonary TB is a 6 month multi drug regimen with two phases – Intensive phase (four 
first line drugs, isoniazid, rifampin, pyrazinamide, and ethambutol) for 2 months and 
continuation phase (Isoniazid and Rifampin alone) for 4 months. Likewise various drug 
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regimens are explored based on the drug susceptibility results, toxicity patterns and 
administration strategies (Example: DOTS) 27, 28 
2.6.1 Isoniazid: 
              Isoniazid (INH), one of the primary drugs in TB treatment today has been in use 
since 1952 due to its efficacy, low toxicity and reasonable cost. When Isoniazid was used 
in a clinical trial for the first time, it was so successful that patients were reported to be 
‘dancing in their wards’. Oxygen is important for the action of INH and it is active 
against growing tubercle bacilli and not the resting organisms. Isoniazid is a “pro” drug 
which needs to be activated by the catalase-peroxidase enzyme which is coded by katG 
gene and once the drug is activated it shows highly specific activity against mycobacteria 
by inhibiting the biosynthesis of mycolic acids which are an essential component of the 
mycobacterial cell wall (36). According to Mitchinson, Isoniazid kills 95% of 
mycobacteria in the first 2 days of treatment while Rifampicin is more effective in the 
continuation phase (28, 29).  
2.6.2 Rifamycins: 
              Rifamycins are among the most potent antibiotics against tubercle bacilli both in 
log and stationary phases. They possess unique characteristics of not only acting rapidly 
after exposure to bacilli but also being bactericidal months after the start of the treatment 
regimen (29). Mechanism of action is by inhibiting an enzyme DNA dependent RNA 
polymerase synthesis through binding to the growing DNA chain (37). 95% of rifamycin 
resistance is due to mutations in a sub unit of this RNA polymerase enzyme (38). 
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2.6.3 Ethambutol: 
              Ethambutol, first introduced in 1961, is still an enigma with respect to its 
mechanism of action and molecular basis for drug resistance. It is believed that it is 
effective against mycobacteria by specifically inhibiting various steps in the bacterial cell 
wall synthesis (39). 
2.6.4 Pyrazinamide:  
               Pyrazinamide, one of the first line drugs has an incredible sterilizing activity 
thus killing the persisting bacilli and enabling the shortening of treatment regimen from 9 
months to 6 months. It is also a prodrug and converted into Pyrazinoic acid by the 
enzyme Pzase produced by M.tuberculosis. Resistance is mostly attributed to mutations 
in this Pzase enzyme (40). 
2.6.5 Streptomycin:  
               Streptomycin, first discovered by Waksman and colleagues in 1941 was 
effective as an anti TB drug previously but not currently used as a mono therapy drug due 
to increase in drug resistance and treatment failure 60. The mode of action of streptomycin 
is inhibition of translation of m RNA and aberrant proofreading 41. 
2.6.6 Fluoroquinolones:  
               Fluoroquinolones are currently used in drug resistance and for those who do not 
tolerate therapy.  In view of changing resistance patterns, they are now considered for 
inclusion as first line agents. The key factor in their mode of action is DNA gyrase and 
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mutations in this enzyme are the most common reason for resistance. Mouse models 
confirm these findings 42.  
2.7 Fighting TB- challenges:  
2.7.1 TB and HIV: 
               Globally around nine percent of TB incidence is attributed to HIV but in some 
regions it is higher- WHO African region (31%) and also in industrialized nation- United 
States (8.6%) 67. Also 12 % of TB deaths are attributed to HIV 14. There are more than 1 
million TB cases in people with HIV. In a HIV infected person, TB is harder to diagnose 
and progresses more rapidly 15.  In addition, HIV infection weakens the immune system 
and increases the probability of getting infected and progressing to active TB 15, 16. 
Studies have shown that co-infection with HIV increases the risk of TB infection 
developing into active TB by 10 fold 68. Out of the 1.8 million persons who died with TB 
in 2007, estimates show that around 456,000 were HIV positive 3. These numbers prove 
that the HIV pandemic poses a massive threat to global TB control programs. 
               Though some adverse drug-drug interactions between HAART (Highly active 
anti retroviral therapy) and TB drugs (rifamycins), DOTS and anti retroviral therapies are 
synergistic and without undergoing both of these therapies in combination, the life 
expectancy of a HIV infected TB patient will be typically less than five years. Emphasis 
on early detection and cure will help in minimizing TB related cases and deaths in a most 
cost effective way according to results shown by mathematical models 45. 
2.7.2 Multidrug resistance:  
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               Multidrug resistant TB (MDR-TB), the condition where Mycobacteria are 
resistant at least to Isoniazid (INH) and Rifampicin (RIF), the two most powerful drugs 
against TB, is one of the huge challenges impeding public health efforts to control 
tuberculosis. Drug resistant TB can occur in two ways- acquired or secondary drug 
resistance and initial (primary) drug resistance. Acquired drug resistance which occurs 
owing to discontinuous and ineffective therapy that selects a small number of resistant 
mutants, is normally seen from 1 to 4 months after initiation of therapy.  Serial exposure 
to inadequate regimens enables the emergence of multi drug resistance.  Initial resistance 
occurs when a person is infected by drug resistant TB strains and can only be 
distinguished from acquired resistance by comparing a patient’s baseline and follow up 
drug susceptibility patterns.  In the absence of microbiology data, it can be inferred by 
knowing the past treatment regimens followed by the patient 31, 32.   
                Though the true levels of multidrug resistance are unknown, according to the 
WHO 2008 estimates, around 440 000 cases of multidrug resistant TB emerged globally, 
implying that around 3.6% of TB incident cases are multi drug resistant (MDR). 
Moreover, national and regional anecdotal evidence points towards an increase in the 
number of drug resistance cases throughout the world. Half of these cases occur in China 
and India, and MDR-TB accounts for approximately 150 000 deaths. The most common 
form of drug resistance in the US is Isoniazid resistance which has been documented in 
10% of TB patients. The standard treatment regimen is not effective against MDR-TB, 
and the alternatives are far more expensive, less potent, more toxic and takes longer for 
effective treatment (at least two years) 30.  
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                According to the Stop TB initiative 2006-2015, there is a huge need for 
resources to address this issue since estimates show that 1.3 million MDR-TB cases will 
need treatment in 27 high MDR-TB burden countries (2010-2015) and this would cost 
USD 16.2 billion. 29,423 MDR-TB cases reported throughout the world in 2008 
represent only 7% of the estimated number of cases that year. The limited surveillance 
for MDR-TB is attributed to deficiency of local laboratory resources and drug 
susceptibility testing to identify incident MDR-TB cases. Only 1% of newly incident 
cases underwent drug susceptibility tests (DST) in 2008. The distressing fact is that only 
1% of the MDR-TB cases identified are enrolled in treatment 30. Increase in Multidrug 
resistance throughout the world underlines the importance of need for accurate DST and 
availability of alternate regimens to these patients. Molecular level understanding of 
medicinal chemistry of anti TB drugs is necessary to understand multidrug resistance. 
Analyzing drug susceptibility results is imperative to address the need for surveillance, to 
propose improved treatment regimen and guidelines, to understand the risk factors in 
proven cases of resistance and several other potential benefits.  
2.8 Current methods for MTB detection and drug susceptibility testing: 
                  Valid and reliable DST is important to design appropriate drug regimens. As 
per the recommendations by the American Thoracic Society, initial isolates from all 
patients must be tested for first line drug resistance (INH, RIF, ETH, and PZA). 
Subsequently, isolates resistant to first line drugs must be tested for resistance to second 
line drugs (fluoroquinolones, amikacin, kanamycin and capreomycin) 50, 69.  DST results 
define clinical resistance using terms ‘susceptible’ and ‘resistant’ based on quantitative 
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analysis. ‘Resistance’ is defined as growth of greater than 1% of bacteria when ‘critical’ 
drug concentration is present. Critical concentration implies the minimum concentration 
of the drug that inhibits 95% of wild strains of MTB.  These concentrations have been 
determined empirically and adopted worldwide 51.  
                   There is an increasing need for development of rapid tests due to the high 
rates of multidrug resistant TB (MDR-TB) and emergence of extensively drug resistant 
TB (XDR-TB). It is highly important to identify cases of MTB and treat them in a timely 
and efficient way. It normally takes 7 to 14 days to detect TB using methods such as 
MGIT (Mycobacterium Growth Indicator) or BACTEC (Becton Dickinson) in 
laboratories that are well established and funded 46. If traditional methods for culturing 
MTB are followed (using Lowenstein-Jensen (LJ) and the less expensive Ogawa media 
for example), it may take an average of 3 weeks for detection alone and DST may take an 
additional 3 to 4 weeks 48.  Lengthy periods for DST tests might lead to adverse 
consequences such as assignment of inappropriate treatment, spread of drug resistance in 
the community and augmentation of resistance in the patient 47. In the developing world 
most TB control programs use stained sputum smears for case finding and mostly the 
treatment regimen is given in the absence of Drug Susceptibility Testing 49.                          
Development of rapid tests will have individual and also public health benefits such as 
enhanced diagnosis, improved survival chances, prevention of acquisition of further drug 
resistance and reduced spread of resistance in the population. Nevertheless, as of now, 
there is no single test which is good, quick, cheap and easy 47. Also most TB cases occur 
in resource-limited countries where costly and sophisticated equipment requiring 
conventional rapid detection methods (BACTEC and MGIT) are not available.   
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                 The National Centre for Clinical Laboratory services recommends the agar 
proportion method which is an inexpensive and comparatively simple method for DST 
testing. The procedure for agar proportion method includes steps such as plating bacteria 
on media with either no drug or critical concentration of the drug and then incubating for 
3 weeks followed by counting of colonies. An isolate is defined as resistant if the number 
of colonies on drug- containing media is greater than 1% of number of colonies on drug-
free media. This method has been a “gold standard” in the US.  In general, for first line 
DST testing in the US, commercial broth systems is used rather than the time-consuming 
agar proportion method. The minimum time for agar proportion method is 21 days 50, 52, 
53
. Nevertheless, second line DST is mostly done using the agar proportion method. FDA- 
cleared rapid broth DST tests exist for first line drugs but not for second line drugs so far 
50
. Due to the emergence of multiple drug resistant TB, the CDC recommended DST on 
all baseline isolates from each patient and repeated testing if the patient was not culture 
converted after 3 months of therapy or failed to respond clinically to the treatment. In 
addition, it is mandatory to report susceptibility results within 4 weeks after receiving the 
specimen. 
                    In the summary report on the TB drug susceptibility testing by the APHA 
and CDC, several issues and concerns about current practices have been raised. Some of 
the problems are due to the differential capabilities of Mycobacteriology labs and the 
discrepancies that arise due to piece-meal services offered at each lab. Inefficient 
communication between labs has been an issue of concern. Lack of confidence in drug 
resistance results leads to continued retesting, further delaying the reporting of results. 
High costs and limited trained laboratory expertise are additional subjects of concern51. 
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2.9 Description of drug treatment testing clinical trials by TB Trials Consortium, CDC 
(Studies- 22, 23, 24, 25, 27, 28 and 29): 
                   CDC Tuberculosis Trials Consortium (TBTC) conducts clinical, 
microbiological and epidemiological research in areas such as diagnosis, clinical 
management and prevention of TB infection and disease. It has several sites in various 
parts of the globe- United States, Canada, Brazil, Peru, Spain, South Africa, Uganda, 
Vietnam and China. For laboratory services, the sites rely on local Mycobacteriology labs 
and also the CDC Mycobacteriology lab which acts as the central lab for confirmatory 
drug susceptibility testing (where second line drug resistance testing is also performed, 
unlike the local labs where only first line drug resistance is tested). Below is a synopsis of 
some of the clinical trials done by TBTC: 
• Study 29 is a prospective, multicentre, open label Phase II clinical trial designed to 
evaluate the efficacy and safety of an experimental intensive phase (first 8 weeks of 
treatment) tuberculosis treatment regimen in which daily Rifapentine is substituted 
for Rifampin in combination with INH, ETH and PZA.  Patients with suspected 
pulmonary tuberculosis and other inclusion criteria were enrolled in the study 43.   
• Study 28 is a multicenter, placebo-controlled, Phase II- double-blind trial designed to 
evaluate the effect of using Moxifloxacin (M) in place of Isoniazid (H), in 
combination with Rifampin (R), Pyrazinamide (Z) and  Ethambutol (E) on 2-month 
culture conversion rates among patients with sputum smear-positive pulmonary 
tuberculosis 44, 70.  
• Study 27 is a double-blind, Phase II, randomized, multicenter study by the 
Tuberculosis Trials Consortium (TBTC) undertaken in United States, Uganda, 
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Canada and Brazil to assess the effect of using Moxifloxacin (Moxi) in place of 
Ethambutol (E), in combination with Isoniazid (H), Rifampin (R), and Pyrazinamide 
(Z) on 2-months culture conversion among patients with sputum smear-positive 
pulmonary tuberculosis28, 72.  
• Study 25 is a prospective, randomized, double-blind study to test the tolerability of 
three different doses (900 mg, 1200mg, 600mg) of Rifapentine in the treatment of 
tuberculosis. HIV seronegative patients with culture positive drug susceptible 
tuberculosis were enrolled into this study59, 73.  
• Study 24 aimed at determining the efficacy of a largely intermittent regimen for INH-
resistant or INH intolerant Tuberculosis. It is a prospective, open-label, 
nonrandomized trial where in the patients enrolled must be sensitive to Rifampin, 
Ethambutol and Pyrazinamide, INH resistant or intolerant58. 
• Study 23 is a non randomized, open label, single arm, prospective study to treat HIV-
Related Tuberculosis and to determine the rate of confirmed treatment failure and 
relapse with an intermittent rifabutin-based regimen for the treatment of Isoniazid and 
Rifamycin-susceptible HIV-related tuberculosis54, 71. 
• Study  22 is an open label, randomized controlled trial to compare, at completion of 
the follow-up phase, the clinical and bacteriologic relapse rates associated with the 
two study regimens- Once-Weekly Rifapentine and Isoniazid compared to twice-
Weekly Rifampin and Isoniazid for treatment of Pulmonary Tuberculosis57, 74. 
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             Studies 23, 27, 28, and 29 enrolled patients at the beginning of intensive 
phase treatment.  Studies 22 and 25 enrolled patients at the beginning of 
continuation phase treatment, after approximately 2 months of TB therapy.  Study 
24 enrolled patients after a period of up to approximately 2 months on pre-study TB 
treatment.
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CHAPTER III 
METHODOLOGY 
3.1 Data Sources and Study Population 
                    The data for this analysis were provided by the Tuberculosis Trials 
Consortium (TBTC), CDC. TBTC conducts programmatically relevant clinical 
trials, partnering with US and international clinical sites to expand the current 
clinical and epidemiologic knowledge of TB and enhance the scope for diagnosis, 
clinical management, and prevention of tuberculosis infection and disease. Data for 
this analysis were collected over nearly two decades (1993-2011), gathered from 7 
clinical trials. Many variables, methods of data collection differ among these 
studies. 
 
3.2 Objectives: 
                 The objectives of this analysis are four-fold for each study (22, 23, 24, 
25, 27, 28 and 29) 
1. Measure the amount of discordance between the DST results done at CDC 
Mycobacteriology laboratory and local site laboratories. 
2. Compute discordance by drug type, drug testing concentration and study sites. 
3. Calculate the Kappa values, the statistic to measure inter rater agreement for 
each antibiotic in each study.
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4. Evaluate the sensitivity and specificity of the local laboratory DST results 
considering CDC results as the ‘gold’ standard. 
5. Determine how much drug resistant MTB exists among the patients entering 
TBTC studies (22, 23, 24, 25, 27, 28 and 29) as most studies assume a pan 
sensitive population.  (The notable exception is Study 24, for which resistance 
to INH was one possible entry criterion.)  
 
3.3 Hypothesis: 
                   For each study, DST results of the CDC Mycobacteriology lab do not differ 
from DST results of public health labs at local TBTC sites. 
 
3.4 Study Design: 
                   All clinical trials conducted by the TBTC have been approved by the 
institutional review boards of CDC and each clinical site. Patients give written informed 
consent before being enrolled into these studies. TBTC, CDC provided this previously 
collected data for secondary analysis free of identifiers. The IRB at Georgia State 
University approved this analysis (Appendix A). 
3.4.1 Common Methodology for all studies for Secondary data analysis: 
                   All analysis was done using SAS 9.2 version (The SAS Institute, Cary, NC). 
Each study ID corresponds to a single participant in that study. All study ids without 
comparable DST results in either CDC dataset or the local lab results dataset were 
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excluded from the analysis. DST results for other antibiotics such as Amikacin which 
were only tested at the CDC Mycobacteriology lab were not considered for analysis.                   
                  After merging the CDC and the local DST results dataset, the records meeting 
the above criteria were considered for further cleaning. Nevertheless there were a few 
study IDs which were present more than once. This might be due to the reasons such as 
the initial culture being non viable, culture contamination (after which the site resubmits 
the isolate) or absence of Mtb growth on susceptibility testing medium. In such a 
scenario, the condition used to pick the right record was matching the variables 
‘date_collected’ (from CDC ) and ‘specdate’(from local labs). These two fields 
‘date_collected’ and ‘specdate’ as discussed above come from two different datasets- 
CDC and local respectively and both the dates indicate when the specimen was collected 
and hence are comparable. Multiple DST results for the same patient exist due to various 
reasons such as culture being contaminated or failing in grow, repetition of lab tests to 
confirm drug resistance, isolates that are not collected at baseline etc. Since one of the 
objectives of the analysis is to capture how much drug resistance exists in the general TB 
population by measuring drug resistance when patients first enroll in the study (Baseline 
isolates- isolate collected at the time of enrollment), it is imperative to pick the baseline 
DST results for the analysis and not include any acquired drug resistance results which 
might sometimes lead to additional discordance.  If repetition of lab tests to confirm drug 
resistance was identified (‘date_collected’ -period is within few months or looking at 
comments section: ‘resend specimen’) the record that have earliest concordant DST 
results was picked. 
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                   Further when the above criteria were met when duplicates and triplicates 
persisted, checking the ‘comments’ field in CDC dataset for information regarding 
culture contamination, isolate resubmission and other factors helped in picking the right 
record. Thus the final cleaned dataset was created for each study based on all the above 
criteria and these datasets was used for not only determining the levels of discordance 
between the two DST results but also to answer all the questions listed in the objectives 
of the analysis. 
3.4.2 Kappa Statistic Analysis: 
3.4.2.1 Background 
                   Kappa statistic, the most commonly used statistic to measure the agreement 
between two or more observers takes into account that observers may agree or disagree 
just by chance. If a kappa value is 1, it indicates perfect agreement while a kappa value of 
0 indicates agreement equal to chance. One of the limitations of Kappa statistic is that it 
is dependent on the prevalence of the condition being tested. Precision (agreement 
between observers) is reported using kappa statistic 61. This statistic is used in situations 
where two or more observers are calculating the same thing- CDC lab DST results and 
Local lab DST results as in this case. The formula for calculation is the based on 
observed agreement and expected agreement (expected due to chance alone). Observed 
agreement (P0) being the ratio of results where both the labs agreed (a+d) to the total 
number of results (N) where (a) and (d) represent the number of times the raters agree, 
(b) and (c) represent the number of times the raters disagree. If N1 is the sum of (a) and 
(c), N0 is the sum of (b) and (d), M1 is the sum of (a) and (b) and M0 is the sum of (c) and 
21 
 
 
(d), then expected agreement (PE) is given by the formula- [((N1/ N)*(M1/ N)) + ((N0/ 
N)*(M0/ N))]. Finally, kappa is calculated as the ratio of (P0 - PE) and (1- PE) 62. 
3.4.2.1 Kappa analysis specifically for DST data analysis:  
                        Kappa statistic was calculated for each antibiotic (Isoniazid (0.2µg/ml), 
Isoniazid (1 µg/ml), Rifampin (1µg/ml), Ethambutol (5µg/ml), Pyrazinamide (100µg/ml), 
Streptomycin (2µg/ml) in each study (22, 23, 24, 25, 27, 28, and 29) using proc freq- 
kappa procedure in SAS 9.2. 
3.4.3 Sensitivity, Specificity and PPV (Positive Predictive Value) analysis: 
                         For each antibiotic, sensitivity and specificity of the local lab DST results 
were measured by first counting the number of true positives, false positives, true 
negatives and false negatives. True positives are those results that tested positive 
(resistant) and were truly positive (resistant) in CDC lab test results. False Positives are 
those that tested positive (resistant) in local lab but tested negative (susceptible) in CDC 
lab. True negatives are those that tested negative (susceptible) in local lab test and were 
truly negative (susceptible) in CDC lab results. False Negatives are those that tested 
negative (susceptible) in local lab test but were positive (resistant) in CDC lab results. 
Sensitivity, the statistical measure signifying the proportion of true positives (antibiotic 
resistant specimens) correctly identified so, was calculated by using the following 
formula: TP/(TP+FN) where TP represents the number of true positives and FN 
represents the number of false negatives. Likewise, specificity represents the proportion 
of true negatives (antibiotic sensitive specimens) correctly identified so is calculated as 
TN/(TN+FP). Positive predictive value which is the ratio of True Positives (TP) and the 
sum of True Positives and false positives (TP+FP) (Denominator: number of patients 
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testing positive for resistant MTB) is the probability that the patient has drug resistant TB  
when restricted to those patients who test positive (resistant) in local lab results. PPV was 
calculated for each antibiotic in each study. 
 
3.4.3 Discordance between the two lab test results is the sum of false positives and false 
negatives. 
                         After measuring the total discordance, discordance by local lab site for 
each study was measured as the sum of false positive and false negatives. Baseline drug 
resistant MTB among the patients entering these clinical trial studies (22, 23, 24, 25, 27, 
28 and 29) was measured as the ratio of number of resistant isolates for each study (per 
antibiotic) measured by both labs-CDC and local and the total number of specimens 
tested for that antibiotic. Discordance is calculated by considering individual DST results 
independently. In other words, there could be multiple discordances for a single isolate 
but each of the discordances is counted independently by drug tested. Similar procedure 
was followed for all other studies with a few differences in variable names and this will 
be discussed in sections below. 
 
3.5 Methodology for each study specifically and variables analyzed: 
3.5.1 Study 29: (Rifapentine substituted for Rifampin) 
Variables analyzed: 
CDC lab results-Variable 
Name 
Comparable-Local lab results-
Variable name 
Label 
PATIENT_ID1 STUDY_ID Study ID number which 
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is unique for each patient 
DATE_COLLECTED SPEC_DATE Date when the specimen 
was collected at site 
DATE_RECEIVED  Date when the specimen 
was received at CDC 
DATE_SENT  Date when the specimen 
was sent to CDC 
RIFAMPIN_1 RIF Rifampin-1µg/ml 
STREPTOMYCIN_2 SM Streptomycin-2µg/ml 
ISONIAZID_0_2 INH_02 Isoniazid-0.2µg/ml 
ISONIAZID_1 INH_1 Isoniazid-1µg/ml 
PYRAZINAMIDE_100 PZA Pyrazinamide-100µg/ml 
ETHAMBUTOL_5 ETH Ethambutol-5µg/ml 
 
                The CDC and local datasets had 402 and 473 records respectively. After 
merging the CDC and the local DST results dataset by study id and taking only the ones 
that have DST results in both there were 359 records. After duplicate records were further 
cleaned by using criteria mentioned and information in the comments section there were 
333 records in the final data set (as there were several duplicates and triplicates) and this 
dataset was used to address the objectives. Sensitivity and specificity and discordance 
were calculated as per the procedure mentioned in 3.d.2 and 3.d.3 respectively 
3.5.2 Study 28 (Moxifloxacin substituted for INH): 
                The variables analyzed were similar to that of Study 29. The CDC and local 
datasets had 522 and 421 records respectively. After merging the CDC and the local DST 
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results dataset the 435 records meeting the criteria mentioned in 3.4.1. After duplicate 
records were further cleaned by using criteria mentioned and information in the 
comments section there were 342 records in the final data set and this dataset was used to 
address the objectives. Sensitivity and specificity and discordance were calculated as per 
the procedure mentioned in 3.4.2 and 3.4.3 respectively. 
3.5.3 Study 27 (Moxifloxacin substituted for Ethambutol): 
Variables analyzed: 
CDC lab results-Variable 
Name 
Comparable-Local lab results-
Variable name 
Label 
LAST_NAME STUDY_ID Study ID number which is 
unique for each patient 
DATE_RECEI  Date when the specimen 
was received at CDC 
SPECIMEN_T  Date when the specimen 
was sent to CDC 
RIF_1 RIF Rifampin-1µg/ml 
SM_2 SM Streptomycin-2µg/ml 
INH_02 INH_02 Isoniazid-0.2µg/ml 
INH_1 INH_1 Isoniazid-1µg/ml 
BACTEC_PZA PZA Pyrazinamide-100µg/ml 
ETHAMBUTOL_5 ETH Ethambutol-5µg/ml 
 
                The CDC and local datasets had 374 and 323 records respectively. Merging the 
CDC and the local DST results dataset records after crosschecking whether they meet the 
criteria mentioned in 3.4.1 was done (351 records). There were 28 distinct patient ids 
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with duplicates. After removing the duplicates, the final cleaned dataset had 321 records 
and this was used for Sensitivity and specificity and discordance analysis as per the 
procedure mentioned in 3.4.2 and 3.4.3. 
3.5.4 Study 25 (tolerability- 600, 900, 1200 mg Rifapentine): 
                 The variables analyzed for this study were exactly similar to that of study 27 
(Except- variable for PZA in CDC dataset was PZA_25).  The CDC and local datasets 
had 158 and 150 records respectively. The merged dataset had 149 records. The final 
cleaned datasets after merging had 135 records meeting the criteria mentioned in 3.4.1. 
The records with comments regarding culture contamination and other culture non-
viability were removed. Also the records which seemingly showed discordance but where 
the comments section had additional information about the results being pending were 
removed from the analysis. Also 2 records that seemingly showed Pyrazinamide (PZA) 
discordance but the comment had information that though the results show resistance the 
cultures were sensitive on another medium were removed as this cannot be considered as 
discordance as there is information about the true drug susceptibility of the culture.  
There was one duplicate and one record with culture contamination –both excluded from 
the final analysis. So the cleaned dataset had 135 records and this was used for Sensitivity 
and specificity and discordance analysis as per the procedure mentioned in 3.4.2 and 
3.4.3. 
 
3.5.5 Study 24 (Alternate regimen for INH intolerant or resistant patients): 
                 The variables analyzed for this study are exactly similar to that of Study 27 
(Except- variable for PZA in CDC dataset was PZA_25). There were 50 and 92 records 
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in the CDC and local datasets respectively. The merged dataset had 50 records. There 
were 4 duplicates. Then the records were cleaned as per the criteria mentioned in 3.4.1 
and the final dataset had 43 records after removing the duplicates. This dataset was used 
for Sensitivity and specificity and discordance analysis as per the procedure mentioned in 
3.4.2 and 3.4.3. 
 
3.5.6 Study 23 (treatment of Isoniazid and Rifamycin-susceptible HIV-related 
tuberculosis):  
                 The variables analyzed for this study are exactly similar to that of Study 27 
(Except- variable for PZA in CDC dataset was PZA_25). There were 191 and 168 
records in the CDC and local datasets respectively. The merged dataset had 172 records. 
There were 15 patient IDs with duplicates. When there were multiple records for the 
same ID, the one that had ‘Final Report’ in comments section were picked. Then the 
records were cleaned as per the criteria mentioned in 3.4.1 and the final dataset had 142 
records after making sure there is no redundancy. . This dataset was used for Sensitivity 
and specificity and discordance analysis as per the procedure mentioned in 3.4.2 and 
3.4.3. 
 
3.5.7 Study 22 (once weekly Rifapentine INH in continuation phase): 
The variables analyzed for this study are exactly similar to that of Study 27 (Except- 
variable for PZA in CDC dataset was PZA_25). There were 1416 and 311 records in the 
CDC and local datasets respectively. The merged dataset had 487 records. There were 
111 distinct patient ids with multiple duplicate records. They were picked based on the 
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field ‘date recei’ such that DST results of the valid isolate were picked for the analysis. 
Then the records were cleaned as per the criteria mentioned in 3.4.1 and the final dataset 
had 303 records after making sure there is no redundancy. For Pyrazinamide, a new 
dataset was created from the final dataset as there were a few records with a null value in 
CDC- DST results for PZA. This new dataset used for PZA alone (271 records) served a 
dual purpose - the records with null values in CDC lab-DST results are not picked up as 
discordance and also other antibiotic related DST results are not lost due to exclusion 
from the analysis. These datasets were used for Sensitivity and specificity and 
discordance analysis as per the procedure mentioned in 3.4.2 and 3.4.3. 
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CHAPTER IV 
RESULTS 
This section describes the answers to the research questions in detail. 
4.1 Discordance analysis:  
4.1.1 STUDY 29: 
The total number of records included in the analysis was 333 (Figure 1). Very good inter 
rater agreement (high kappa value) was found for INH and RIF (Table 14). Due to the 
high number of false negatives for Pyrazinamide (PZA), Ethambutol (EMB) and 
Streptomycin (SM), the sensitivity was very low. No discordance was observed for 
Rifampin (RIF) leading to 100% sensitivity, specificity and Positive predictive value. 
Drug resistant population at baseline (%) was calculated as the ratio of number of true 
positives and total number of records analyzed multiplied by hundred to understand the 
drug resistance pattern in patients enrolling into these studies. The drug resistance at 
baseline in Isoniazid (both concentrations-especially (1µg/ml)) was found to be high 
(8.25% and 11.34% respectively) (Table 1). 
Discordance between the two labs for each antibiotic was also categorized by site to 
identify frequent discordances so that appropriate recommendations for local lab resource 
strengthening can be made (Table 8).
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4.1.2 STUDY 28: The total number of records included in the analysis was 342 (Figure 
2). High Kappa values were found for INH and RIF (Table 15). Low sensitivity was 
observed for PZA whereas high specificity was documented for INH (both 
concentrations) and Rifampin. Drug resistant population at baseline (%) was calculated as 
per above discussion in Study 29 results and highest was found in INH (1µg/ml). 
Discordance between the two labs for each antibiotic was also categorized by site (Table 
9).  
4.1.3 STUDY 27: The total number of records included in the analysis was 321 (Figure 
3). ETH and SM had very high kappa values (Table 16). Ethambutol (ETH) had 100% 
sensitivity, specificity and positive predictive value (PPV) whereas INH (1µg/ml) and 
SM had high specificity and PPV. INH (0.2µg/ml) had low sensitivity (Table 3). There 
were no PZA DST results in CDC dataset. Drug resistant population at baseline (%) was 
calculated as per above discussion in Study 29 results and it was highest in INH 
(0.2µg/ml) - 10.31% when compared to all other antibiotics. Discordance between the 
two labs for each antibiotic was also categorized by site. Site 30 had 10 discordances 
(INH (0.2 µg/ml) alone) given the higher N (total patients tested) value after comparing 
the results with the gold standard- CDC (Table 9).  
4.1.4 STUDY 25: The total number of records included in the analysis was 135 (Figure 
4). The fewer number of records in the final dataset compared to other studies might 
explain the low drug resistance found in this study-25 (Table 3). Discordance between the 
two labs for each antibiotic was also categorized by site (Table 10).  
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4.1.5 STUDY 24: The total number of records included in the analysis was 43 (Figure 5). 
High Kappa value was found for INH (1µg/ml) (Table 18). Drug resistant population at 
baseline (%) was found to be very high for INH (75.76% and 40.74% for both 
concentrations) which is reasonable as the requirement to be a part of this study is INH 
resistance or intolerance (Table 4). Discordance between the two labs for each antibiotic 
was also categorized by site (Table 10).  
4.1.6 STUDY 23: The total number of records included in the analysis was 142 (Figure 
5). High kappa statistic was found for INH (0.2µg/ml), INH (1µg/ml) and PZA (Table 
19). Sensitivity was particularly low for Streptomycin (SM) whereas specificity was 
almost 100% for all antibiotics (Table 5). Higher PZA resistance at baseline (around 
13%) was found in this study. Discordance between the two labs for each antibiotic was 
also categorized by site (Table 11).  
4.1.7 STUDY 22: The total number of records included in the analysis for PZA were 271 
where as for all the other antibiotics - 303 (Figure 7).  There were no local lab results for 
INH (1µg/ml). The two lab DST results agreed less than would be expected just by 
chance alone for PZA and ETH and overall the Kappa values were lower when compared 
to other studies (Table 20). Sensitivity was low for INH (0.2µg/ml), SM and RIF. PPV 
and specificity were 100% for INH (0.2µg/ml) (Table 7). SM had the highest drug 
resistance at baseline (around 6%). Discordance between the two labs for each antibiotic 
was also categorized by site (Table 14).  
Overall statistics (Table 22) indicate a total discordance percentage of 7.786% (N=1708) 
and an average kappa value of 0.6444 which indicates good agreement overall. A closer 
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look indicates lowest kappa value for study 22 (0.2216) and highest agreement for study 
23 (0.8497). Though it might not be appropriate to calculate average values (across all 
studies) for kappa, sensitivity, specificity, PPV and discordance due to several reasons 
mentioned in Discussion section, the calculations were done only to indicate overall 
values. High specificity (97.75) and low sensitivity (70.24) were found overall. Average 
positive predictive value across all studies was 77.96%. 
 
Box Plots for Kappa statistic and Positive predictive values across studies (Figures 3 and 
4): 
                 All kappa values that are zero or undefined were excluded from the box plots 
for Positive predictive values and kappa statistics. Especially in the case of Kappa 
statistic- a calculated value of zero resulted as no drug resistance was observed for that 
antibiotic in that study. So it actually means perfect agreement even though the kappa 
value is zero. 
              The median for kappa statistic were mostly closer across different studies even 
though the range was large. For study 22- there were no local lab results for Isoniazid 
(INH) at 1 µg/ml concentration. Also there were negative kappa values for 2 antibiotics.  
In all the studies clumping of lower values is seen (especially study 24 and 27). 
             A Box plot for positive predictive values (for each antibiotic) across studies was 
drawn. In case of no drug resistance for a particular antibiotic, the positive predictive 
value is not defined. These cases were excluded for drawing the box plot. Most often the 
lower values are clumped but the range is high. For study 25 there was no drug resistance 
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found except in streptomycin, so the box plot is entirely based on the values from 
Streptomycin. 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
5.1. Discussion 
                      There are numerous striking variations in the objective of each clinical trial, 
the clinical disease status of participants (though all have active TB – some have 
pulmonary, extra pulmonary, HIV, cavitation, etc), participating sites (some changed 
over time), number of patients enrolled at each site, number of patients enrolled in each 
study, number, concentration of antibiotics tested for drug susceptibility, and test method 
at each site and in each study.  
                       Also the long time span between the earliest and the later studies (1997-
2010) creates variability in the emphasis placed on DST, pursuing local sites to resend 
specimens in case cultures are contaminated or failed to grow, the resources available for 
DST and sophistication of methods used for testing.  
                       Merely combining the results of all studies and calculating pooled values 
without paying attention to the variations will be inappropriate. However, among all 
studies DST results are compared between a local lab and CDC lab for paired isolates 
from each patient.  Therefore, merging the results just to get an overall picture of trends 
over time by site was helpful to make appropriate recommendations. Nevertheless, all 
these variations need to be considered while examining the results.  
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The isolates sent to CDC laboratory are subcultures of the original culture used for local 
lab tests. This might influence the capacity to identify low level resistance at CDC lab. 
Another factor that might influence discordance is the lack of indication of partial drug 
resistance at the local lab. Local lab DST results only indicate whether the isolate is 
resistant or susceptible unlike the CDC lab where drug resistance is expressed as 
percentage.  For this analysis, any percentage drug resistance above 0 at CDC lab was 
considered as ‘resistant’.  
                      The eligibility criteria for each study vary and this has significant impact on 
the various measures computed. Patients in Study 29, 28 and 27 are enrolled prior to 
being tested for drug resistance during intensive phase therapy. Patients in study 24 are 
known to be infected with M. tuberculosis resistant to Isoniazid (primary) or are 
intolerant to INH at the time of enrollment.  Patients in study 23 are HIV seropositive 
adults with positive cultures for TB, known to be susceptible to INH and Rifampin at 
enrollment. Patients in study 22 were tested in the continuation phase of therapy, having 
been eligible to enroll with a baseline isolate susceptible to INH and Rifamycin. Thus,  
Drug-resistance rates between studies are partly attributable to differences in study 
design.  Studies that enrolled later in the course of TB therapy would be expected to find 
lower rates of drug resistance, since patients with drug resistance would more likely have 
been discovered and excluded from the study, except for Study 24, which had higher 
rates of INH-resistance by design.  DST can take a month or two in the laboratory, due to 
the slow growth of MTB in culture. 
                        The current global drug resistance percentages for Isoniazid are 6·7% 
(IQR 4·2–11·6) 63. According to the Global surveillance for anti tuberculosis drug 
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resistance, 1994-1997, primary drug resistance to Isoniazid (7.3 percent) or streptomycin 
(6.5 percent) was more common than resistance to Rifampin (1.8 percent) or Ethambutol 
(1.0 percent) 64. Similar trend was observed in all studies (except study 23). For Study 24, 
the baseline drug resistance for INH and SM was very high compared to other TBTC 
studies. This is expected as being INH intolerant or INH resistant is one of the inclusion 
criteria. 
                          Discordance rates for Study 27, 28 and 29 (tested after enrollment- 
resistance at enrollment is not known) were not unusually different from the other studies 
(Studies 22, 23 and 25 – DST results known at enrollment) (Table 22). However, 
employing rapid tests for determining drug resistance prior to initiating treatment at sites 
where rates of drug resistance is high would be beneficial.  Such screening would avoid 
starting patients on sub optimal treatment regimens, who are later found to have baseline 
drug resistant TB. 
                         Though overall statistics for kappa, sensitivity, specificity, Positive 
predictive value and discordance % have been calculated for all studies combined, results 
should be interpreted with caution due to all the mentioned variations. Box plot for kappa 
statistic across studies was done. There was skewed distribution in all studies and it might 
be concluded that with time the concordance between the two lab results improved for the 
most part based on the distribution of kappa values. 
5.2 Limitations of the Study: 
• Considering each antibiotic DST results for single patient independently might be a 
problem especially if discordance exists in several antibiotic DST results for the same 
isolate.  
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• Due to the variable number of patients at each site and in each study, it is difficult to 
give equal value for their results. 
• The time span between the earliest and latest studies is around 11 years which might 
have impact in the sophistication of methods used, resources available, the emphasis 
on the importance of DST results 
• Some local sites did not test certain antibiotics (or certain antibiotics at different 
concentrations) which resulted in an irregular distribution of sites testing the 
antibiotics and these were excluded from the analysis. Thus the total number of 
records will not reflect the number of valid unique DST results. These variations need 
to be considered while interpreting the results. 
• In this analysis discordance was not measured by DST method, which might play a 
role in outcome of DST.  
• Kappa statistic is influenced by base rates of diagnosis and might not be appropriate 
to compare across studies with different base rates. 
 
5.3 Recommendations 
                 Timely detection of drug resistance in patients is most important to prevent 
a worldwide epidemic of incurable multidrug resistant tuberculosis even though rarity 
of resistance is the rule, for now. Most often, underestimation of the problem rather 
than affordability is currently paralyzing laboratory services to detect resistance. 
Since the currently available methods are all laboratory based, it is understandable 
that at least for the next few years, avoiding lab based methods is not possible. 
Currently traditional approaches using phenotype (culture media detecting drug 
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resistance based methods) are in use. The minimum inhibitory concentration ranges 
(MIC s) or critical concentration ranges (between resistant and susceptible strains) 
vary for each drug and the gap (range) indicates whether the lab based test is reliable 
for that antibiotic. Drugs such as Isoniazid (INH) and rifampin (RIF) have wide gap 
between the highest MIC s for susceptible strains and lowest MIC s for resistant 
strains, thus improving the reliability of the DST results55.   Literature shows that for 
drugs such as Ethambutol (ETH) the difference is narrow and this might give rise to a 
number of false positives and false negatives56.  
                   There are several rapid and sensitive genotypic methods also but their 
affordability is the issue of concern. Though the current results show few DST 
results discordances between local and CDC labs, it is better to continue to send 
isolates to the centralized lab (CDC) (even though it means more investment) in 
view of the worldwide threat of drug resistant TB epidemic, the recommendations 
of the current literature 51, 56 and the benefits of reliable confirmatory testing 
services and availability of other molecular diagnostic methods.  The key role that 
local laboratories play by providing timely DST reporting to clinicians, which is 
critical for tailoring effective drug regimens to treat patients is also recognized.  
 
5.4 Conclusion 
Though the current results show few DST result discordances between local and 
CDC labs, it is better to continue to send isolates to the centralized lab (CDC) in 
view of the worldwide threat of drug resistant TB epidemic, the recommendations 
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of the current literature and the benefits of reliable confirmatory testing services and 
availability of other molecular diagnostic methods. 
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TABLES 
Table 1: Comparison of discordance results for antibiotics in Study 29 
Antibiotic 
(µg/ml) 
True 
Positiv
es (TP) 
False 
Positive
s 
(FP) 
True 
Negatives 
(TN) 
False 
Negativ
es 
(FN) 
Sensitivit
y (%) 
Specifici
ty (%) 
Positive 
Predictive 
Value 
(PPV) 
Discord
ance 
(FP+FN
) 
Drug resistant population at 
baseline (%)((TP+FN)/N 
*100)) 
N=TP+FP+TN+FN 
Isoniazid (0.2) 22 1 277 3 88 99.64 95.65 4 8.25 
Isoniazid (1) 9 1 85 2 81.81 98.83 90 3 11.34 
Rifampin (1) 9 0 322 0 100 100 100 0 2.72 
Pyrazinamide 
(25) 
2 1 231 5 28.57 99.56 90 6 2.93 
Ethambutol (5) 1 0 324 6 14.28 100 100 6 2.11 
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Streptomycin 
(2) 
9 3 270 9 50 98.90 75 12 6.19 
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Table 2: Comparison of discordance results for antibiotics in Study 28 
Antibiotic 
(µg/ml) 
True 
Positiv
es (TP) 
False 
Positiv
es 
(FP) 
True 
Negatives 
(TN) 
False 
Negativ
es 
(FN) 
Sensitivit
y (%) 
Specificity 
(%) 
PPV Discordan
ce 
(FP+FN) 
Drug resistant 
population at 
baseline 
(%)(TP/N*100) 
Isoniazid (0.2) 20 0 289 2 90.90 100 100 2 7.07 
Isoniazid (1) 8 0 111 1 88.88 100 100 1 7.50 
Rifampin (1) 4 0 337 1 80 100 100 1 1.46 
Pyrazinamide 
(25) 
3 2 257 2 60 99.22 60 4 1.89 
Ethambutol (5) 0 2 337 0 - 99.41 - 2 0.00 
Streptomycin 
(2) 
9 5 284 2 81.81 98.26 64.28 7 3.67 
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Table 3: Comparison of discordance results for antibiotics in Study 27 
Antibiotic 
(µg/ml) 
True 
Positive
s (TP) 
False 
Positive
s 
(FP) 
True 
Negatives 
(TN) 
False 
Negative
s 
(FN) 
Sensitivi
ty (%) 
Specificity 
(%) 
PPV Discordan
ce 
(FP+FN) 
Drug resistant 
population at 
baseline 
(%)((TP+FN)/N)
*100) 
Isoniazid (0.2) 15 2 233 12 55.55 99.14 88.23 14 10.31 
Isoniazid (1) 2 0 108 1 66.66 100 100 1 2.70 
Rifampin (1) 3 1 309 2 60 99.67 75 3 1.59 
Pyrazinamide 
(25) 
2 1 243 2 50 99.59 66.66 3 1.61 
Ethambutol (5) 4 0 311 0 100 100 100 0 1.27 
Streptomycin (2) 10 0 262 1 90.90 100 100 1 4.03 
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Table 4: Comparison of discordance results for antibiotics in Study 25 
Antibiotic 
(µg/ml) 
True 
Positive
s (TP) 
False 
Positive
s 
(FP) 
True 
Negatives 
(TN) 
False 
Negative
s 
(FN) 
Sensitivit
y (%) 
Specificity 
(%) 
PPV (%) Discordan
ce 
(FP+FN) 
Drug resistant 
population at 
baseline 
(%)((TP+F)/N 
*100) 
Isoniazid (0.2) 0 0 87 0 - 100 - 0 0.00 
Isoniazid (1) 0 1 71 0 - 98.61 - 1 0.00 
Rifampin (1) 0 1 133 0 - 99.25 - 1 0.00 
Pyrazinamide 
(25) 
0 0 59 2 - 100 - 2 3.28 
Ethambutol (5) 0 2 125 0 - 98.42 - 2 0.00 
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Streptomycin (2) 2 3 94 0 100 96.90 40 3 2.02 
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Table 5: Comparison of discordance results for antibiotics in Study 24 
Antibiotic 
(µg/ml) 
True 
Positi
ves 
(TP) 
False 
Positiv
es 
(FP) 
True 
Negative
s 
(TN) 
False 
Negativ
es 
(FN) 
Sensitivi
ty (%) 
Specificit
y (%) 
PPV (%) Discordance 
(FP+FN) 
Drug resistant 
population at baseline 
(%)(TP+FN/N 
*100) 
Isoniazid 
(0.2) 
23 4 4 2 92 50 85.18 6 75.76 
Isoniazid (1) 11 2 14 0 100 87.5 84.61 2 40.74 
Rifampin (1) 0 0 43 0 - 100 - 0 0.00 
Pyrazinamide 
(25) 
0 0 26 1 - 100 - 1 3.70 
Ethambutol 0 0 43 0 - 100 - 0 0.00 
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(5) 
Streptomycin 
(2) 
6 2 20 3 66.66 90.90 75 5 29.03 
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Table 6: Comparison of discordance results for antibiotics in Study 23 
Antibiotic 
(µg/ml) 
True 
Positiv
es (TP) 
False 
Positiv
es 
(FP) 
True 
Negatives 
(TN) 
False 
Negativ
es 
(FN) 
Sensitivi
ty (%) 
Specificity 
(%) 
PPV (%) Discorda
nce 
(FP+FN) 
Drug resistant 
population at 
baseline  
Isoniazid (0.2) 3 0 89 1 75 100 100 1 4.30 
Isoniazid (1) 2 0 87 0 100 100 100 0 2.25 
Rifampin (1) 0 0 134 3 - 100 - 3 2.19 
Pyrazinamide 
(25) 
2 0 68 8 20 100 100 8 12.82 
Ethambutol (5) 0 0 139 0 - 100 - 0 0.00 
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Streptomycin 
(2) 
4 1 110 5 44.44 99.09 80 6 7.50 
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Table 7: Comparison of discordance results for antibiotics in Study 22 
Antibiotic 
(µg/ml) 
True 
Positives 
(TP) 
False 
Positive
s 
(FP) 
True 
Negatives 
(TN) 
False 
Negative
s 
(FN) 
Sensitivit
y (%) 
Specificity 
(%) 
PPV (%) Discordanc
e 
(FP+FN) 
Drug resistant 
population at 
baseline 
(%)(TP/N*100) 
Isoniazid (0.2) 1 0 236 5 16.66 100 100 5 2.48 
Isoniazid (1) No Local Lab results for Isoniazid (1) 
Rifampin (1) 1 4 234 3 25 98.31 20 7 1.65 
Pyrazinamide 
(25) 
0 1 73 4 0 98.64 - 5 5.13 
Ethambutol (5) 0 3 235 1 0 98.73 - 4 0.42 
Streptomycin 
(2) 
8 3 198 5 61.53 98.50 72.72 8 6.07 
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Table 8: Discordance by local site –Study 29 
Antibiotic (µg/ml) 
 
Sites and Frequency of discordance No. of patients at 
each site 
Discordance % 
Isoniazid (0.2) 20 2 22 9.09 
22 1 8 12.50 
40 1 30 3.33 
Isoniazid (1) 20 2 22 9.09 
28 1 10 10.00 
Streptomycin (2) 24 2 16 12.50 
30 4 144 2.78 
31 2 15 13.33 
40 2 30 6.67 
62 2 25 8.00 
Pyrazinamide (25) 13 1 9 11.11 
20 2 22 9.09 
30 2 144 1.39 
70 1 3 33.33 
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Ethambutol (5) 20 1 22 4.55 
30 2 144 1.39 
31 1 15 6.67 
40 2 30 6.67 
Rifampin (1) -   
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Table 9: Discordance by local site –Study 28 
Antibiotic (µg/ml) 
 
Sites and Frequency of discordance No. of patients at 
each site 
Discordance %= 
(freq of 
discordance/No. of 
patients)*100 
Isoniazid (0.2) 17 1 10 10.00 
32 1 27 3.70 
Isoniazid (1) 32 1 27 3.70 
Streptomycin (2) 16 1 10 10.00 
29 1 18 5.56 
30 3 190 1.58 
40 1 19 5.26 
66 1 3 33.33 
Pyrazinamide (25) 16 1 10 10.00 
30 1 190 0.53 
32 2 27 7.41 
Ethambutol (5) 16 1 10 10.00 
30 1 190 0.53 
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Rifampin (1) 14 1 3 33.33 
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Table 10: Discordance by local site –Study 27 
Antibiotic (µg/ml) 
 
Sites and Frequency of discordance No. of patients at 
each site 
Discordance % 
Isoniazid (0.2) 24 1 3 33.33 
30 10 168 5.95 
32 3 36 8.33 
Isoniazid (1) 25 1 3 33.33 
Streptomycin (2) 30 1 168 0.60 
Pyrazinamide (25) 22 1 13  7.69 
32 2 36 5.55 
Ethambutol (5) - - -  -  
Rifampin (1) 13 1 15 6.67 
15 1 10 10.00 
30 1 168 0.60 
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Table 11: Discordance by local site –Study 25 
Antibiotic (µg/ml) 
 
Sites and Frequency of discordance No. of patients at 
each site 
Discordance % 
Isoniazid (0.2) - - - - 
Isoniazid (1) 20 1 32 3.13 
Rifampin (1) 20 1 32 3.13 
Pyrazinamide (25) 25 2 11 18.18 
Ethambutol (5) 54 1 7 14.29 
70 1 8 12.50 
Streptomycin (2) 20 1 32 3.13 
61 1 6 16.67 
62 1 4 25.00 
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Table 12: Discordance by local site –Study 24 
Antibiotic (µg/ml) 
 
Sites and Frequency of 
discordance 
No. of patients at each site Discordance % 
Isoniazid (0.2) 13 1 1 100.00 
14 1 1 100.00 
21 1 5 20.00 
22 1 4 25.00 
40 1 6 16.67 
59 1 3 33.33 
Isoniazid (1) 40 1 6 16.67 
59 1 3 33.33 
Streptomycin (2) 21 1 5 20.00 
22 1 4 25.00 
26 1 2 50.00 
40 2 6 33.33 
Pyrazinamide (25) 22 1 4 25.00 
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Ethambutol (5) - - -  - 
Rifampin (1) - - -  - 
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Table 13: Discordance by local site –Study 23 
Antibiotic (µg/ml) 
 
Sites and Frequency of discordance No. of patients at 
each site 
Discordance % 
Isoniazid (0.2) 22 1 3 33.33 
Isoniazid (1) - -  -  - 
Streptomycin (2) 17 1 24 4.17 
20 1 15 6.67 
62 3 14 21.43 
68 1 8 12.50 
Pyrazinamide (25) 17 4 24 16.67 
28 3 7 42.86 
53 1 2 50.00 
Ethambutol (5) - - -  - 
Rifampin (1) 17 1 24 4.17 
22 1 3 33.33 
70 1 10 10.00 
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Table 14: Discordance by local site –Study 22 
Antibiotic (µg/ml) 
 
Sites and Frequency of discordance No. of patients at 
each site 
Discordance % 
Isoniazid (0.2) 18 1 46 2.17 
20 1 40 2.50 
51 1 6 16.67 
53 1 5 20.00 
61 1 17 5.88 
Isoniazid (1) No Local lab results for this antibiotic   
Streptomycin (2) 17 1 8 12.50 
20 3 40 7.50 
51 1 6 16.67 
55 1 4 25.00 
59 2 9 22.22 
Pyrazinamide (25) 13 1 9 11.11 
18 1 46 2.17 
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51 1 6 16.67 
64 1 17 5.88 
65 1 11 9.09 
Ethambutol (5) 18 3 46 6.52 
51 1 6 16.67 
Rifampin (1) 13 1 9 11.11 
16 1 5 20.00 
17 1 8 12.50 
51 1 6 16.67 
59 1 9 11.11 
61 1 17 5.88 
64 1 17 5.88 
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Table 15: Study 29- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 303 0.9095 Very good agreement 
INH (1) 97 0.8398 Very good agreement 
RIF (1) 331 1 Perfect agreement 
PZA (25) 239 0.3893 Fair Agreement 
ETH (5) 331 0.2460 Fair Agreement 
SM (2) 291 0.5792 Moderate agreement 
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Table 16: Study 28- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 311 0.9490 Very good agreement 
INH (1) 120 0.9368 Very good agreement 
RIF (1) 342 0.8875 Very good agreement 
PZA (25) 264 0.5924 Moderate agreement 
ETH (5) 339 TP=0;FN=0;TN=337;FP=2;No 2*2 table 
Calculated value=0 
Not feasible to calculate 
Kappa values for non-square 
tables (using SAS);  
SM (2) 300 0.7082 Good agreement 
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Table 17: Study 27- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 262 0.6543 Good agreement 
INH (1) 111 0.7956 Good agreement 
RIF (1) 315 0.6619 Good agreement 
PZA (25) 248 0.5654 Moderate agreement 
ETH (5) 315 1 Perfect Agreement 
SM (2) 273 0.9505 Very good agreement 
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Table 18: Study 25- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 87 TP=FP=FN=0;TN=87;  
No 2*2 table; 
Calculated value=undefined 
Not feasible to calculate 
Kappa values for non-square 
tables (using SAS); Since there 
is no discordance, kappa can 
be interpreted as 1 
INH (1) 72 0.9861 Very good agreement 
RIF (1) 134 TP=FN=0; TN=133;FP=1; 
No 2*2 table; 
 Calculated value=0 
Not feasible to calculate 
Kappa values for non-square 
tables (using SAS); There is 
discordance (due to FP), 
nevertheless a kappa of 0 is 
calculated. 
PZA (25) 61 TP=FP=0; TN=59;FN=2; 
No 2*2 table; 
Calculated value=0 
Not feasible to calculate 
Kappa values for non-square 
tables; There is discordance 
(due to FN), nevertheless a 
kappa of 0 is calculated. 
ETH (5) 127 TP=FN=0;FP=2;TN=125; 
No 2*2 table; 
Calculated value=0 
Not feasible to calculate 
Kappa values for non-square 
tables; There is discordance 
(due to FP), nevertheless a 
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kappa of 0 is calculated 
SM (2) 99 0.5587 Moderate agreement 
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Table 19: Study 24- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 33 0.4590 Moderate agreement 
INH (1) 27 0.8508 Very good agreement 
RIF (1) 43 TP=FP=FN=0;TN=43; 
No 2*2 table; 
Calculated=undefined 
Not feasible to calculate Kappa 
values for non-square tables; 
Not feasible to calculate Kappa 
values for non-square tables 
(using SAS); Since there is no 
discordance, kappa can be 
interpreted as 1 
PZA (25) 27 TP=FP=0;TN=26;FN=1; 
No 2*2 table 
Calculated=0 
Not feasible to calculate Kappa 
values for non-square tables; 
There is discordance (due to 
FN), nevertheless a kappa of 0 
is calculated 
ETH (5) 43 TP=FP=FN=0;TN=43; 
No 2*2 table; 
Calculate=not defined 
Not feasible to calculate Kappa 
values for non-square tables; 
Not feasible to calculate Kappa 
values for non-square tables 
(using SAS); Since there is no 
discordance, kappa can be 
interpreted as 1 
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SM (2) 31 0.5953 Moderate agreement 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
62 
 
 
Table 20: Study 23- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 93 0.8517 Very good agreement 
INH (1) 89 1 Perfect agreement 
RIF (1) 137 FP=TP=0;TN=134;FN=3; 
No 2*2 table 
Not feasible to calculate Kappa 
values for non-square tables; 
Not feasible to calculate Kappa 
values for non-square tables; 
There is discordance (due to 
FN), nevertheless a kappa of 0 
is calculated 
PZA (25) 78 1 Perfect agreement 
ETH (5) 139 TP=FN=FP=0;TN=139; 
No 2*2 table; 
Calculated= not defined 
Not feasible to calculate Kappa 
values for non-square tables; 
Not feasible to calculate Kappa 
values for non-square tables 
(using SAS); Since there is no 
discordance, kappa can be 
interpreted as 1 
SM (2) 120 0.5472 Moderate Agreement 
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Table 21: Study 22- Kappa statistic and interpretation 
Antibiotic (µg/ml) N Simple Kappa Coefficient Interpretation 
INH (0.2) 242 0.2806 Fair 
INH (1)  No Local Lab DST results - 
RIF (1) 242 0.2077 Fair 
PZA (25) 78 
 
-0.0209 The two lab results agreed less 
than would be expected just by 
chance 
ETH (5) 239 
 
-0.0063 The two lab results agreed less 
than would be expected just by 
chance 
SM (2) 214 0.6470 Good 
 
• Poor agreement = Less than 0.20  
• Fair agreement = 0.20 to 0.40  
• Moderate agreement = 0.40 to 0.60  
• Good agreement = 0.60 to 0.80  
• Very good agreement = 0.80 to 1.00  
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Table 22: Overall Statistics for all studies 
Study 
Number 
% Discordance Kappa Statistic Kappa 
Interpretation 
Sensitivity Specificity PPV 
22 (29/303)*100= 9.57 0.2216 Fair 
Agreement 
34.396 (3) 98.836 (6) 64.24 (3) 
23 (18/142)*100= 
12.67 
0.8497 Very good 
agreement 
59.86 (4) 99.848 (6) 95 (4) 
24 (14/58)*100= 24.13 0.6350 Good 
agreement 
86.22 (3) 88.06 (6) 81.59 (6) 
25 (9/135)*100= 6.66 0.5587 Moderate  
agreement 
100 (1) 98.86 (6) 40 (1) 
27 (22/351)*100= 6.26 0.7712  Good 
agreement 
70.51 (6) 99.73 (6) 88.315(6) 
28 (17/382)*100= 4.45 0.8147  Very good 
agreement 
80.318 (5) 99.48 (6) 84.856 (5) 
29 (31/337)*100=9.19 0.6603 Good 
agreement 
60.44 (6) 99.48(6) 91.775(6) 
 Total Discordance 
% = 
(133/1708)*100= 
7.786% 
 
0.6444(Average 
Values across 
all studies ) 
Good 
Agreement 
Avg:70.24 Avg: 97.75 Avg:77.968 
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Table 23: Data cleaning methodology (record particulars) for all studies 
Study 
number 
No. of records in CDC 
dataset 
No. of records in local 
dataset 
No. of records is merged dataset 
(after exclusion of records with no 
match in either datasets) 
No. of records in final 
dataset (after removal 
of duplicates and 
further cleaning using 
information in 
comments section) 
29 402 473 359 333 
28 522 421 435 342 
27 374 323 351 321 
25 158 150 149 135 
24 50 92 50 43 
23 191 168 172 142 
22 1416 311 487 303 (PZA dataset:271) 
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Figure 1: Model diagram of methodology for data cleaning (All studies) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ‘X’ records in CDC Dataset ‘Y’ records in Local Dataset 
‘Z’ records after exclusion of 
records with no match in either 
datasets 
‘A’ records after exclusion of 
duplicates 
‘N’ records in final dataset after 
excluding records where any DST 
result at CDC had comments such 
as pending results or culture failed 
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Figure 2: Box Plot- Positive predictive values (PPV) across studies 
 
 
Figure 3: Box Plot- Kappa Statistics across studies 
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APPENDIX A 
INSTITUTIONAL REVIEW BOARD 
 
 Mail: P.O. Box 3999  In Person: Alumni Hall 
  Atlanta, Georgia  30302-3999 30 Courtland St, Suite 217 
 
 Phone: 404/413-3500 
 Fax:  404/413-3504 
 
 
January 25, 2011 
Principal Investigator: Rothenberg, Richard B 
Protocol Department: Institute of Public Health  
Protocol Title: Concordance of Drug Susceptibility test data between CDC Mycobacteriology 
Laboratory and Local Public Health Laboratories in drug efficacy testing trials by TB trials 
Consortium, CDC. 
 
Submission Type: Protocol H11285 
Review Type: Exempt Review 
Approval Date: January 25, 2011 
 
The Georgia State University Institutional Review Board (IRB) reviewed and approved your IRB 
protocol entitled Concordance of Drug Susceptibility test data between CDC Mycobacteriology 
Laboratory and Local Public Health Laboratories in drug efficacy testing trials by TB trials 
Consortium, CDC..  The approval date is listed above.  
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Exempt protocols do not require yearly renewal.  However, if any changes occur in the protocol 
that would change the category of review, you must re-submit the protocol for IRB review.  
When the protocol is complete, a Study Closure Form must be submitted to the IRB. 
 
Any adverse reactions or problems resulting from this investigation must be reported 
immediately to the University Institutional Review Board.  For more information, please visit our 
website at www.gsu.edu/irb. 
 
Sincerely, 
 
Cynthia A. Hoffner, IRB Vice-Chair 
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